Skip to content

Silexion Therapeutics Corp

SLXN SLXNW

CIK 0002022416

← back to feed
Revenue (TTM)
—
Q1 May 2026
Net Income (TTM)
−$10.23M
+27.9% YoY Q1 May 2026
EPS Diluted (TTM)
$11.89
−97.7% YoY Q1 May 2026
Gross Margin
—
Q1 May 2026
Operating Margin
—
Q1 May 2026
Net Margin
—
Q1 May 2026
Free Cash Flow (TTM)
−$11.46M
Q1 May 2026
Cash
$2.41M
Q1 May 2026
Total Debt
—
Q1 May 2026
Shares Outstanding
4.19M sh
Q1 May 2026

Revenue & Net Income

EPS (Diluted)

Cash Flow

Revenue Growth (YoY)

No data available for this metric.

Balance Sheet

Cash vs Debt

Recent filings